Hamilton Health Sciences

Running trials

• Recruiting

  Switching to the IL-23 Inhibitor Guselkumab for People With Active IBD Who Previously Used Ustekinumab (SHIFT-IBD)

  NCT07245394· TIDHI Innovation Inc.· Source

• Recruiting

  Treating Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction: Ablation or Medication

  NCT07272902· Nova Scotia Health Authority· Source

• Recruiting

  Safety in Adult Participants With Atrial Fibrillation Who Are Treated With Anticoagulation

  NCT07175428· Phase 2· Regeneron Pharmaceuticals· Source

• Recruiting

  Comparison of Medical RESCUE Strategies for Patients With Steroid-refractory Acute Severe Ulcerative Colitis

  NCT06660693· Phase 3· McMaster University· Source

• Recruiting

  Safety and Efficacy of Intravenous Thrombolysis in Patients With Ischemic Stroke and Direct Oral Anticoagulants Intake

  NCT06571149· Phase 4· Insel Gruppe AG, University Hospital Bern· Source

• Recruiting

  A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

  NCT06623422· Phase 3· Merck Sharp & Dohme LLC· Source

• Recruiting

  Pericardiotomy in Cardiac Surgery

  NCT06486636· Population Health Research Institute· Source

• Recruiting

  RAFT - Pace &Ablate

  NCT06299514· Habib Khan· Source

• Recruiting

  COLchicine and Thiamine in Heart Failure Due to Ischemic Heart Disease

  NCT05873881· Phase 3· Hamilton Health Sciences Corporation· Source

• Recruiting

  The Fourth Left Atrial Appendage Occlusion Study

  NCT05963698· Hamilton Health Sciences Corporation· Source

• Recruiting

  ALLIANCE AVIV: Safety and Effectiveness of the SAPIEN X4 Transcatheter Heart Valve in Failing Aortic Bioprosthetic Valves

  NCT05172973· Edwards Lifesciences· Source

• Recruiting

  A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of NXT007 in Persons With Severe or Moderate Hemophilia A

  NCT05987449· Phase 1/2· Hoffmann-La Roche· Source

• Recruiting

  Left vs Left Randomized Clinical Trial

  NCT05650658· Baylor College of Medicine· Source

• Recruiting

  A Study of Reduced Dosing of the Nonavalent HPV Vaccine in Women Living With HIV

  NCT05495906· Phase 4· University of British Columbia· Source

• Active, not recruiting

  Physiology-guided vs Angiography-guided Non-culprit Lesion Complete Revascularization for Acute MI & Multivessel Disease

  NCT05701358· Population Health Research Institute· Source

• Active, not recruiting

  Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer

  NCT05445778· Phase 3· AbbVie· Source

• Recruiting

  Anteroposterior Versus Anterolateral Electrode Position for Electrical Cardioversion of Atrial Fibrillation

  NCT05511389· McMaster University· Source

• Active, not recruiting

  Clinical Trial on Agitation in Alzheimer's Dementia

  NCT05543681· Phase 2· IGC Pharma, LLC· Source

• Recruiting

  Screening Donors, Fecal Microbiota Transplant Program in Ulcerative Colitis

  NCT04926103· Hamilton Health Sciences Corporation· Source

• Active, not recruiting

  A Study to Evaluate Overall Health, Physical Activity, and Joint Outcomes in Participants With Severe or Moderate Hemophilia A Without Factor VIII Inhibitors on Emicizumab Prophylaxis

  NCT05181618· Phase 4· Hoffmann-La Roche· Source

• Active, not recruiting

  Study With Elranatamab Versus Lenalidomide in Patients With Newly Diagnosed Multiple Myeloma After Transplant

  NCT05317416· Phase 3· Pfizer· Source

• Active, not recruiting

  COMBINE-INTERVENE: COMBINEd Ischemia and Vulnerable Plaque Percutaneous INTERVENtion to Reduce Cardiovascular Events

  NCT05333068· Diagram B.V.· Source

• Recruiting

  CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock

  NCT05267886· Phase 4· Ottawa Heart Institute Research Corporation· Source

• Recruiting

  A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma

  NCT04910568· Phase 1· Genentech, Inc.· Source

• Active, not recruiting

  A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

  NCT04961567· Phase 3· Biogen· Source

• Recruiting

  Nabilone for Agitation Blinded Intervention Trial

  NCT04516057· Phase 3· Sunnybrook Health Sciences Centre· Source

• Recruiting

  Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement

  NCT04634240· University of British Columbia· Source

• Active, not recruiting

  Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults

  NCT04370054· Phase 3· Pfizer· Source

• Active, not recruiting

  SELUTION SLR™ 014 In-stent Restenosis

  NCT04280029· M.A. Med Alliance S.A.· Source

• Active, not recruiting

  Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial

  NCT03947619· Abiomed Inc.· Source

• Enrolling by invitation

  A Study Following Males With Haemophilia B on Prophylaxis With Refixia/REBINYN

  NCT03745924· Novo Nordisk A/S· Source

• Recruiting

  Clinical Monitoring Strategy Versus Electrophysiology-guided Algorithmic Approach With a New LBBB After TAVI

  NCT03303612· Montreal Heart Institute· Source

• Active, not recruiting

  EARLY TAVR: Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis

  NCT03042104· Edwards Lifesciences· Source

• Active, not recruiting

  LEADERS FREE II: BioFreedom™ Pivotal Study

  NCT02843633· Biosensors Europe SA· Source

• Recruiting

  The Canadian Children Inflammatory Bowel Disease Network (CIDsCaNN)

  NCT02308917· The Hospital for Sick Children· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Atrial fibrillation5 recruiting
• Heart failure4 recruiting
• Ulcerative colitis4 recruiting
• Aortic stenosis3 recruiting
• Stroke3 recruiting
• Haemophilia2 recruiting
• Alzheimer disease1 recruiting
• Coronary artery disease1 recruiting
• Crohn's disease1 recruiting
• HIV1 recruiting
• Lung cancer1 recruiting

Closed trials

• Completed

  A Study on Cytomegalovirus (CMV) Infection Outcomes Among Hematopoietic Stem Cell Transplant (HSCT) Participants in Europe and Canada

  NCT05571137· Takeda· Source

• Completed

  A Study of Milvexian in Participants After a Recent Acute Coronary Syndrome

  NCT05754957· Phase 3· Janssen Research & Development, LLC· Source

• Terminated

  Hemophilia Non-Interventional Study Prior to SerpinPC Intervention (PRESent-5)

  NCT05605678· ApcinteX Ltd· Source

• Completed

  IBD Neoplasia Surveillance RCT

  NCT05809999· Ottawa Hospital Research Institute· Source

• Terminated

  The Efficacy and Safety of Cobitolimod in Participants With Moderate to Severe Active Left-Sided Ulcerative Colitis

  NCT04985968· Phase 3· InDex Pharmaceuticals· Source

• Completed

  Combination Therapy With Fecal Microbiota Transplantation and Vedolizumab for Induction of Ulcerative Colitis

  NCT04231110· Phase 4· McMaster University· Source

• Completed

  Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced/Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015/E7080-G000-321/LEAP-015)

  NCT04662710· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Safety and Efficacy of a Switch to Doravirine/Islatravir in Participants With HIV-1 (MK-8591A-017)

  NCT04223778· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)

  NCT04223791· Phase 3· Merck Sharp & Dohme LLC· Source

• Completed

  EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)

  NCT03950076· Phase 4· Population Health Research Institute· Source

• Completed

  Observational Study of Patients With Moderate to Severe Chronic Plaque Psoriasis

  NCT03982394· AbbVie· Source

• Completed

  The SAPIEN 3 Ultra System in Intermediate Risk Patients With Symptomatic, Severe Aortic Stenosis

  NCT03471065· Edwards Lifesciences· Source

• Completed

  Study to Investigate CSL112 in Subjects With Acute Coronary Syndrome

  NCT03473223· Phase 3· CSL Behring· Source

• Terminated

  Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF

  NCT02387229· Phase 3· Montreal Heart Institute· Source

• Withdrawn

  Improving Outcomes After Time Sensitive Prehospital Interventions: Rescu Epistry

  NCT04110912· Unity Health Toronto· Source

• Completed

  Resynchronization/Defibrillation for Ambulatory Heart Failure Trial in Patients With Permanent Atrial Fibrillation

  NCT01994252· Ottawa Heart Institute Research Corporation· Source

• Completed

  Vascular Events In Surgery patIents cOhort evaluatioN - Cardiac Surgery

  NCT01842568· Population Health Research Institute· Source